FDA Updates Standards List for Device Makers
Published Date: 2/19/2026
Notice
Summary
The FDA just updated its official list of standards that medical device makers can use to prove their products are safe and effective. These changes, effective February 19, 2026, help companies speed up the approval process by following clear, recognized rules. If you’re in the medical device world, this means smoother reviews and no surprise costs or delays!
Analyzed Economic Effects
3 provisions identified: 3 benefits, 0 costs, 0 mixed.
Updated recognized standards list
The FDA published modifications to its list of recognized consensus standards that are applicable February 19, 2026. You are a medical device manufacturer if you elect to declare conformity with these standards to meet parts of premarket review submissions, and the FDA says the publication will assist those manufacturers in meeting certain device requirements.
Many standards withdrawn and replaced
The notice lists specific recognized consensus standards that the FDA is withdrawing, correcting, revising, or replacing with newer versions (for example, many ISO and ASTM standards across anesthesiology, biocompatibility, cardiovascular, dental, orthopedics, materials, and other device areas). These changes are incorporated under "Recognition List Number: 065" and are applicable February 19, 2026.
Searchable database and ongoing updates
FDA is incorporating these Recognition List Number: 065 modifications into its searchable database (accessible via FDA websites) and states it will announce additional modifications once a year or more often if needed. You can use the searchable database to find the current FDA-recognized consensus standards.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-13047 — Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-13140 — Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of Oxygenation
The FDA is officially putting the monitor for opioid-induced oxygen problems into a safer, easier-to-manage category called Class II. This change helps make sure the device works well and is safe, while also speeding up patient access to this important tech. The new rules took effect on June 30, 2026, and could lower costs and delays for companies making these monitors.
2026-13139 — Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of Hyperhidrosis
The FDA is officially classifying the skin patch that treats excessive sweating (hyperhidrosis) as a Class II device, meaning it has special safety rules but fewer hurdles than the strictest category. This change helps patients get access to this cool new treatment faster and safer, starting June 30, 2026. Companies making these patches will find it easier and less costly to bring their products to market.
2026-13005 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; New Animal Drugs for Minor Use and Minor Species
The FDA is asking for public feedback on their plan to keep collecting info about new animal drugs for rare uses and less common species. This affects drug makers who want special approval and incentives for these unique animal medicines. Comments are open until July 29, 2026, and the process helps keep these important drugs safe and available without extra costs.
2026-13006 — Determination of Regulatory Review Period for Purposes of Patent Extension; VYALEV
The FDA has officially set the review period for the drug VYALEV, which helps the company extend its patent protection. This means the patent clock can be paused, giving the drug maker more time to sell VYALEV exclusively. If anyone thinks the dates are wrong or the company wasn’t diligent, they can speak up by late 2026.
2026-13101 — Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock Absorber
The FDA is officially classifying the medial knee implanted shock absorber as a Class II device, meaning it has special safety rules but fewer hurdles than the strictest category. This change helps patients get access to this innovative knee device faster and with confidence in its safety. The new classification is effective June 29, 2026, and could save time and money for makers and users alike.
Previous / Next Documents
Previous: 2026-03309 — Indian Energy Service Center; Receipt of Tribal Energy Resource Agreement for the Southern Ute Indian Tribe of the Southern Ute Reservation, Colorado
The Southern Ute Indian Tribe in Colorado has submitted a Tribal Energy Resource Agreement (TERA) that lets them manage energy projects on their land without needing extra government approval. The Department of the Interior is reviewing this agreement and wants public comments by March 23, 2026. If approved, this will speed up energy deals and give the Tribe more control over their resources.
Next: 2026-03311 — Agency Information Collection Activities; Proposed Collection; Comment Request; Procedures for the Safe Processing and Importing of Fish and Fishery Products
The FDA wants your thoughts on how they collect info about safely processing and importing fish and seafood. This affects businesses that handle fish products, aiming to keep seafood safe and clean. You’ve got until April 20, 2026, to share your comments—no fees, just your voice helping shape safer seafood rules!